Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Clinical trial NCT05282797 · COMPLETED

Trial details

NCT number: NCT05282797
Sponsor: Anebulo Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Cannabinoid Intoxication

Start date: 2021-12-15
Primary completion: 2023-08-26
Enrollment: 154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.